Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blenrep Maintenance After Salvage ASCT in RRMM
NCT05065047Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belantamab mafodotin in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Treatment-Related Adverse Events at 1 year and Pain Scores on the Visual Analog Scale at 6 weeks. Started Jan 2023; status: terminated.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05065047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05065047.